3-[(cyclopentylsulfanyl)methyl]-4-methoxy-N-phenylbenzenecarboximidamide | 1569736-45-3

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯酚醚
• 英文名称: 3-[(cyclopentylsulfanyl)methyl]-4-methoxy-N-phenylbenzenecarboximidamide
• 英文别名: 3-(cyclopentylsulfanylmethyl)-4-methoxy-N'-phenylbenzenecarboximidamide
• CAS: 1569736-45-3
• 化学式: C₂₀H₂₄N₂OS
• 分子量: 340.489
• InChiKey: AZWSPEWRPOQSSX-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  4.3
• 重原子数：
  24
• 可旋转键数：
  6
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.35
• 拓扑面积：
  72.9
• 氢给体数：
  1
• 氢受体数：
  3

反应信息

• 作为产物：
  描述：

  环戊硫醇 在 tris(dibenzylideneacetone)dipalladium(0) chloroform complex 、 N,N-二甲基乙酰胺 、 三甲基铝 、 potassium carbonate 、 锌 、 2-二环己基磷-2,4,6-三异丙基联苯 作用下， 以 N,N-二甲基甲酰胺 、 甲苯 为溶剂， 反应 3.83h， 生成 3-[(cyclopentylsulfanyl)methyl]-4-methoxy-N-phenylbenzenecarboximidamide
  参考文献：
  名称：

  New Hits as Antagonists of GPR103 Identified by HTS

  摘要：

  Preclinical data indicate that GPR103 receptor and its endogenous neuropeptides QRFP26 and QRFP43 are involved in appetite regulation. A high throughput screening (HTS) for small molecule GPR103 antagonists was performed with the clinical goal to target weight management by modulation of appetite. A high hit rate from the HTS and initial low confirmation with respect to functional versus affinity data challenged us to revise the established screening cascade. To secure high quality data while increasing throughput, the binding assay was optimized on quality to run at single concentration. This strategy enabled evaluation of a larger fraction of chemical clusters and singletons delivering 17 new compound classes for GPR103 antagonism. Representative compounds from three clusters are presented. One of the identified clusters was further investigated, and an initial structure activity relationship study is reported. The most potent compound identified had a pIC(50) of 7.9 with an improved ligand lipophilic efficiency.

  DOI：

  10.1021/ml400519h

文献信息

• New Hits as Antagonists of GPR103 Identified by HTS
  作者：Anneli Nordqvist、Lisbeth Kristensson、Kjell E. Johansson、Krystle Isaksson da Silva、Tomas Fex、Christian Tyrchan、Anette Svensson Henriksson、Kristina Nilsson

  DOI：10.1021/ml400519h

  日期：2014.5.8

  Preclinical data indicate that GPR103 receptor and its endogenous neuropeptides QRFP26 and QRFP43 are involved in appetite regulation. A high throughput screening (HTS) for small molecule GPR103 antagonists was performed with the clinical goal to target weight management by modulation of appetite. A high hit rate from the HTS and initial low confirmation with respect to functional versus affinity data challenged us to revise the established screening cascade. To secure high quality data while increasing throughput, the binding assay was optimized on quality to run at single concentration. This strategy enabled evaluation of a larger fraction of chemical clusters and singletons delivering 17 new compound classes for GPR103 antagonism. Representative compounds from three clusters are presented. One of the identified clusters was further investigated, and an initial structure activity relationship study is reported. The most potent compound identified had a pIC(50) of 7.9 with an improved ligand lipophilic efficiency.